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ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether or not pitolisant 
is effective in reducing excessive daytime sleepiness and cataplexy in adults with narcolepsy.  
 
Study Design: Review of two randomized control trials (RCTs) published in 2013 and 2017, and 
one prospective, placebo-controlled, single-blind study published in 2008.  
 
Data Sources: All articles were published in English and taken from peer-reviewed journals, 
which were found using the PubMed database.  
 
Outcomes Measured: The outcomes of investigation measured include excessive daytime 
sleepiness (EDS) assessed by change in Epworth Sleepiness Scale (ESS) score, and cataplexy 
rate calculated from recorded cataplexy attacks in patients’ sleep diaries.  
 
Results: Dauvilliers, et al. found pitolisant was more effective in reducing mean ESS scores 
from baseline compared to placebo (-5.8 vs -3.4; p=0.024). A decrease in ESS score indicates 
improved EDS. Also, in post-hoc analyses, Dauvilliers et al. found that pitolisant was superior to 
placebo in reducing daily cataplexy rate from baseline (0.38 vs 0.92; p=0.034). Szakacs, et al. 
found pitolisant to be effective in reducing weekly cataplexy rate (WCR) by 75% from baseline 
compared to placebo (38% decrease in WCR), p <0.0001; they also report a significant decrease 
in ESS score from baseline in the pitolisant group compared with placebo (-5.4 vs -1.9; p= 
0.0001). In a single-blind, placebo-controlled, prospective study, Lin et al. found that tiprolisant 
(currently called pitolisant) showed a significant reduction in ESS score from baseline compared 
to placebo (5.9 vs 1.0; p<0.001).  
  
Conclusions: Pitolisant was shown to be efficacious in reducing EDS and cataplexy in adults 
with narcolepsy.  
  
Key Words: Narcolepsy, pitolisant, tiprolisant 
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INTRODUCTION 
Narcolepsy is a rare, chronic neurological disorder characterized by excessive daytime 
sleepiness (EDS) causing an individual to fall asleep at inappropriate times throughout the day, 
which can disrupt work, school, and social life. According to DSM-5 criteria, EDS occurs at 
least three times per week for at least three months with at least one of the following: cataplexy 
(at least a few times per month), shortened rapid eye movement (REM) latency of ≤15 minutes 
on polysomnography (or a multiple sleep latency test (MSLT) showing a mean sleep latency of 
≤8 minutes and ≥2 sleep-onset REM periods), and hypocretin deficiency in CSF.1 Cataplexy is 
defined as a sudden, brief loss of muscle tone associated with intense emotions (may have global 
hypotonia without emotional triggers, which is seen in children or when onset of disease is 
within six months), without loss of consciousness.  
Narcolepsy usually presents in the teens or early twenties and has two peak onsets: ages 
15-25 and 30-35 years.1 It affects 1 in 2,000 people in the US.2 Cataplexy often occurs within a 
year in 50% of those diagnosed and affects 0.02 – 0.04% of the general population worldwide.1 
Unfortunately, more than 80% of individuals with sleep disorders remain undiagnosed, which 
costs the US economy over $400 billion per year in medical costs, decreased/lost productivity, 
injuries, and screening programs.2 Literature reports a mean delay in diagnosis of narcolepsy of 
up to 15 years, consequentially impacting the burden of disease.3 Individuals with narcolepsy 
have a two to three-fold higher annual rate of inpatient admissions, and visits to the ED, hospital 
outpatient centers, neurologist, pulmonologist, and PCP.4, 5 Studies have shown that the annual 
average cost per patient for medical services and medications is more than double the amount for 
patients with narcolepsy compared to matched controls ($11,702 vs $5261; p <0.0001).4  
The exact etiology and pathogenesis of narcolepsy remain unclear, but a few causes have 
been identified: genetics, decreases in hypocretin (orexin) neuropeptides, and destruction/loss of 
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orexin neurons. Orexins are excitatory neuropeptides that project to histaminergic or 
noradrenergic neurons known to play a key role in wakefulness.6 All patients with narcolepsy 
suffer from EDS; other symptoms include abnormal REM sleep manifestations such as cataplexy 
(most common and most debilitating), hallucinations and sleep paralysis, which intrude into their 
wakefulness and vice versa, greatly impairing the person’s quality of life.2, 5  
The usual method of treating narcolepsy combines lifestyle changes plus stimulants or 
CNS depressants. Lifestyle changes include improving sleep hygiene by establishing a regular 
sleep schedule, getting at least seven hours of sleep per night, taking short naps throughout the 
day, daily exercise, and avoiding shift work. Psychostimulants such as modafinil, 
methylphenidate, or amphetamine/dextroamphetamine are commonly used as wake-promoting 
therapies to treat EDS.2, 7 CNS depressants such as sodium oxybate is currently the only drug that 
is FDA approved for both cataplexy and EDS in adults.7, 8 Antidepressants such as SSRIs, 
SNRIs, and TCAs are used off-label for cataplexy, however supporting evidence is scarce.7 
Narcolepsy is a lifelong, debilitating disorder with no cure currently available. EDS and 
cataplexy are the two most commonly reported symptoms and known to significantly impact 
daily living. Since only one drug is FDA approved to treat both EDS and cataplexy, some 
patients must manage their symptoms with multiple medications. Sodium oxybate, while 
effective at treating both EDS and cataplexy, can however cause serious adverse effects and 
requires an inconvenient nightly dosing administration, in which the patient needs to set an alarm 
2.5 to 4 hours later to take the second dose. Thus, a need exists for more safe and convenient 
drugs that can treat both EDS and cataplexy. Studies have shown that histamine neurons play a 
significant role in maintaining wakefulness9 and patients with the most severe loss of orexin 
neurons tend to show the highest increase in histaminergic neurons in narcolepsy,10 providing a 
targeted area of study in which to activate histaminergic transmissions for arousal. Research 
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demonstrates H1 and H3 histamine receptors in the brain are important in mediating the wake-
promoting effects of histamine.9 Studies suggest pitolisant, a histamine H3-receptor inverse 
agonist, activates these histaminergic neurons to release histamine and in turn increase 
wakefulness, thereby treating EDS and cataplexy in adults with narcolepsy. This review 
evaluates two randomized controlled trials (RCTs) and a prospective, single-blind, placebo-
controlled trial comparing the efficacy of pitolisant in reducing EDS and cataplexy in adult 
patients with narcolepsy.    
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not pitolisant is 
effective in reducing excessive daytime sleepiness and cataplexy in adults with narcolepsy.  
METHODS 
 All selected articles were published in English, in peer-reviewed journals, and found on 
the PubMed database using the following search terms: “Narcolepsy”, “pitolisant”, and 
“tiprolisant.” Articles were selected based on relevance to the stated clinical question and 
whether or not the outcomes mattered to patients. The inclusion criteria were placebo-controlled, 
single or double-blind primary resource studies, with at least two being RCTs, published no more 
than 10 years ago. Studies with patients younger than 18 years of age and initial/baseline ESS 
scores of less than 10 were excluded.  Statistics reported in this review include mean change 
from baseline, confidence intervals, p-values, relative benefit increase (RBI), relative risk 
reduction (RRR), absolute risk reduction (ARR), absolute benefit increase (ABI), and numbers 
needed to treat (NNT). Demographics and characteristics of each study are provided in Table 1. 
This review examines two double-blind, placebo-controlled RCTs and one prospective, 
sequential placebo-controlled, single-blind trial. The patient population selected for this review 
included individuals at least 18 years of age diagnosed with narcolepsy with or without 
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cataplexy. The intervention under study was pitolisant (formerly called tiprolisant and BF2.649), 
a selective histamine H3 receptor inverse agonist. Comparisons were made against a control 
group receiving a placebo. Outcomes measured were patient oriented and included EDS 
(assessed by Epworth Sleepiness Scale (ESS) score) and cataplexy rate based on those reported 
in patients’ sleep dairies. 
Table 1: Demographics and Characteristics of included studies  
Study Type # 
Pts 
Age 
(yrs) 
Inclusion Criteria Exclusion 
Criteria 
W/D Interventions 
Dauvilliers 
(2013)11   
Double-blind, 
placebo-
controlled, 
parallel-group 
RCT 
95 ≥18 ● Pts ≥18yo with 
narcolepsy       
+/- cataplexy, no 
psychostimulants for 
≥14 days 
● have EDS  
(ESS score ≥14) 
● Self-reported EDS 
for >3mo 
● Narcolepsy 
confirmed by 
polysomnogram 
● multiple sleep 
latency test (MSLT) 
within 5yrs – mean 
sleep latency (MSL) 
of ≤ 8min with ≥2 
REM periods 
● Use of IND 
within 30 days 
before screening 
● any disorder 
(d/o) that could 
cause EDS in 
those without 
cataplexy 
● history of 
substance abuse, 
CVD, liver or 
renal 
abnormalities, or 
psych disorders 
1 Pitolisant 
(10mg, 20mg, 
or 40mg/day), 
4 cap, po once 
daily in AM x 
8wks 
(3wks flexible 
dosing followed 
by 5wks stable 
dosing) 
 
Szakacs 
(2017)12 
Double-blind, 
placebo-
controlled 
RCT 
106 ≥18 ● Pts ≥18yo with 
narcolepsy with 
cataplexy (≥3/wk) 
● have EDS (ESS 
score ≥12) 
● Narcolepsy 
confirmed by 
polysomnogram 
● MSLT within 1yr 
and ≥2 REM periods  
● Use of any 
psychostimulant 
or sedative meds 
● Participation in 
another trial 
within a month 
before screening 
● History of any 
other d/o with 
EDS, substance 
abuse, CVD, 
liver/renal 
abnormalities, or 
a psych d/o 
1 Pitolisant 
(5mg, 10 mg, 
20 mg, or 
40mg), 1cap 
po once daily 
in AM  
x 7wks  
(3wks flexible 
dosing followed 
by 4wks stable 
dosing) 
Lin  
(2008)13  
Pilot, 
prospective, 
comparative, 
sequential 
placebo-
controlled, 
single-blind 
22 ≥28 ● Adults with 
narcolepsy with 
cataplexy   
● EDS with 2≤ 
direct onset REM 
periods and a MSL 
<8mins during an 
MSLT 
● ESS score <10 
 
0 Tiprolisant 
40mg, 1 cap 
po once daily 
in AM x 
1week 
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OUTCOMES MEASURED 
 The outcomes measured were change in EDS and cataplexy rate with pitolisant versus 
placebo. In all three articles, EDS was assessed by change in mean ESS score from baseline.11-13 
The ESS is a self-administered questionnaire that subjectively measures and screens for EDS by 
assessing the chance of falling asleep in eight ordinary life situations. Each item on the scale is 
graded from 0 – 3; thus, the score can range from 0 (normal, with no chance of falling sleep) to a 
max of 24 (severe EDS). A decrease in ESS score indicates improved EDS and an ESS score of 
10 or lower is considered normal.14 Dauvilliers et al. and Szakacs et al. also gave additional post-
hoc analysis and secondary endpoint analysis, respectively, of dichotomous data on ESS 
responder rates, defined as patients with a final ESS (ESSf) score of 10 or lower.
11, 12 Cataplexy 
rates were calculated from the mean number of attacks reported in patients’ individual sleep 
diaries. Szakacs et al. and Dauvilliers et al. report weekly and daily (defined as ≥1 cataplexy 
attacks during baseline or treatment period) cataplexy rate reduction from baseline, respectively, 
as the ratio of final weekly cataplexy rate divided by the corresponding baseline (WCRf/b). In a 
secondary analysis, Szakacs et al. also gave dichotomous data on the proportion of patients who 
had a weekly cataplexy rate (WCR) >15 at the end of the treatment study.12 The post-hoc and 
secondary assessments were completed in order to confirm differences between the pitolisant and 
placebo groups.  
RESULTS 
All three studies used in this review aim to demonstrate the efficacy of pitolisant on EDS 
and/or number of cataplexy attacks by verifying whether the results of pitolisant are superior to 
those of placebo. Two double-blinded RCTs assessed both reduction of EDS and cataplexy, 
while one single-blinded trial assessed only reduction in EDS. All studies consisted of 
participants from multiple sleep centers in Europe. The inclusion and exclusion criteria of all 
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three articles are comparable (Table 1), and all patients who received at least one study dose 
were included in the intention-to-treat analysis. Prior to baseline (preceding randomization) 
patients discontinued psychostimulants, but were permitted to continue anticataplectic agents 
(sodium oxybate or antidepressants, except TCAs due to effect on H1 receptors in the brain and 
drug interactions with pitolisant) throughout the trial. In each of the studies, change in arithmetic 
mean ESS score was calculated. To test the superiority of pitolisant over placebo, they then 
adjusted for baseline values to show treatment effect between the groups.  
In Dauvilliers et al.11 95 patients were randomly assigned to treatment: 30 to placebo, 32 
to pitolisant, and 33 to modafinil. However, comparisons with modafinil are not included in this 
EBM review. One patient was lost from the pitolisant group due to withdrawal of consent (before 
receiving any treatment), leaving 94 patients in the intention-to-treat analysis, and 57 (61%) of 
which who had cataplexy. Double-blinding was maintained throughout the eight-week treatment 
phase and all patients were given four capsules per day, matched to placebo in taste and 
appearance, despite their assigned treatment or dose. The treatment period consisted of 3 weeks 
of flexible dosing (10mg, 20mg, or 40mg/day of pitolisant adjusted for individual clinical 
efficacy and safety) followed by 5 weeks of stable, assigned dosing.11 Change in mean ESS score 
from baseline was the primary analysis of this study. They found pitolisant was more effective in 
reducing mean ESS scores from baseline compared to placebo (-5.8 vs -3.4; p=0.024; table 2). 
In a double-blinded, RCT conducted by Szakacs et al.,12 106 patients with cataplexy were 
randomly assigned to treatment: 54 to pitolisant and 52 to placebo. One patient was lost from the 
placebo group due to injury unrelated to the trial; since they never received a dose they were not 
included in the intention-to-treat analysis. The treatment phase lasted 7 weeks: 3 weeks of 
flexible dosing (5mg, 10mg, or 20mg/day of pitolisant) followed by 4 weeks of stable, assigned 
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dosing (5mg, 10mg, 20mg, or 40mg pitolisant). Change in mean WCR from baseline was the 
principle outcome of this study.   
Lin et al.13 conducted a pilot, prospective, single-blinded two-week study of 22 patients 
(21 with cataplexy), all whom were included in the intention-to-treat analysis. Without knowing 
the sequence, patients were given 1 week of placebo followed by 1 week of a fixed dose of 
tiprolisant 40mg/day. Unlike the other two trials, each participant acted as their own control. The 
principle outcome of this study was change in mean ESS score from baseline (Table 2).  
P-values of less than 0.05 indicate that there is a less than 5% chance that improvement in 
ESS scores occurred by chance and that there is a statistically significant difference in change in 
ESS score from baseline compared to placebo. The researchers used continuous data to present 
these findings, which is provided in Table 2. Despite change in ESS scores being negative or 
positive, all values indicate reduction of points from baseline. In each study reviewed, patients 
given pitolisant had a greater reduction in mean change of ESS score from baseline compared to 
placebo, indicating statistically significant improvement (reduction) in EDS.  
Table 2: Comparison of change in mean ESS score from baseline compared to placebo 
Study Pitolisant Placebo Treatment effect (95% CI) P-Value 
Dauvilliers, et al. 11 -5.8 (SD 6.2) -3.4 (SD 4.2) -3.0 (-5.6 to -0.4) 0.024 
Szakacs, et al. 12 -5.4 -1.9 -3.48 (-5.03 to -1.92) 0.0001 
Lin, et al. 13 5.9 (SD 5.5) 1.0 (SD 4.9) 4.9 (2.22 to 7.56) 0.0006 
 
 In the two double-blinded RCTs11,12 additional dichotomous data on the percentage of 
ESS responders (defined as patients with final ESS scores (ESSf) ≤ 10 after the treatment study) 
were used to further determine efficacy of pitolisant. An ESS score of ≤ 10 is considered within 
normal range. In a post-hoc analysis conducted by Dauvilliers et al.11 45% (14/31 patients) of 
patients given pitolisant have reported an ESSf ≤10, compared to 13% (4/30 patients) of those 
given placebo (p<0.0006, 95% CI: 4.4 (2.1–9.2)). Similarly, in a secondary efficacy assessment 
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conducted by Szakacs et al.12 39% (20/51 patients) of patients given pitolisant reported an ESSf 
≤10, compared to 18% (9/50 patients) given placebo (p = 0.035, 95% CI: 3.28 (1.08–9.92)). 
Determining the numbers needed to treat (NNT) value establishes clinical significance of the 
intervention. The NNT values of 3 and 5 mean that for every 3 or 5 patients with narcolepsy 
treated with pitolisant, one more patient will report an ESSf ≤ 10 (improved EDS) compared to 
those receiving a placebo (Table 3). 
Table 3: Comparison of ESS responders (final ESS ≤ 10) between pitolisant and placebo  
Study Control 
Event Rate 
(CER) 
Experimental 
event rate 
(EER) 
Relative 
benefit 
increase (RBI) 
Absolute 
benefit 
increase (ABI) 
Number 
needed to 
treat (NNT) 
P-Value 
 
Dauvilliers, 
et al. 11 
0.13 0.45 2.46 0.32 3 <0.0006 
Szakacs, et 
al. 12 
0.18 0.39 1.17 0.21 5 0.035 
 
In the RCT conducted by Szakacs et al.12 the primary outcome was change in geometric 
mean of WCR from baseline, which is reported as the ratio of final weekly cataplexy rate divided 
by the corresponding baseline (WCRf/b). These results are recorded as continuous data and 
provided in Table 4. This study found pitolisant to be effective in reducing WCR by 75% 
(WCRf/b = 0.25) from baseline compared to placebo (38% decrease in WCR, WCRf/b = 0.62, p 
<0.0001, Table 4). The p-value listed in Table 4 indicates that WCR was reduced significantly 
with pitolisant compared to placebo.    
Table 4: Change in mean WCR from baseline of the Szakacs, et al.12 RCT 
Treatment Baseline Final Change 
(Final/Baseline) 
Treatment effect  
(95% CI) 
P-Value 
Pitolisant (n=54) 9.15 2.27 0.25 0.51 (0.43–0.60) < 0.0001 
Placebo (n=51) 7.31 4.52 0.62 
 
 Dauvilliers et al.11 gave additional post-hoc analysis on the change in geometric mean of 
daily cataplexy rate from baseline. These results are recorded as continuous data and provided in 
Table 5 below. This analysis included only the patients who reported in their sleep diaries at least 
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one cataplexy attack during baseline or during the 8-week treatment phase. Pitolisant reduced 
daily cataplexy rate by 62% (0.38) from baseline versus 8% in those taking placebo (0.92). 
Pitolisant was effective and superior to placebo in reducing mean cataplexy rate from baseline 
(p= 0.034, Table 5).  
Table 5: Change in mean daily cataplexy rate from baseline of the Dauvilliers, et al.11 RCT  
Treatment Baseline  
(SD) 
Final  
(SD) 
Change 
(Final/Baseline) 
Treatment effect  
(95% CI) 
P-Value 
Pitolisant (n=20) 0.52 (0.6) 0.18 (0.4) 0.38 0.38 (0.16–0.93) 0.034 
Placebo (n=14) 0.43 (0.7) 0.39 (0.6) 0.92 
 
Szakacs et al.12 conducted a secondary analysis on the proportion of patients with a final 
WCR greater than 15. This dichotomous data showed 7% (4/54 patients) of patients given 
pitolisant reported a final WCR >15, compared to 24% (12/51 patients) of those given placebo. 
The percentage of patients reporting high cataplexy rate was significantly decreased with 
pitolisant versus placebo, with p-value = 0.005. The NNT value of -6 means that for every 6 
patients with narcolepsy and cataplexy treated with pitolisant, one less patient will report 
severely high WCR (WCR>15) compared to those taking placebo (Table 6).   
Table 6: Proportion of patients with final WCR >15 between pitolisant and placebo  
Study Control 
Event Rate 
(CER) 
Experimental 
event rate 
(EER) 
Relative risk 
reduction 
(RRR) 
Absolute risk 
reduction 
(ARR) 
Number 
needed to 
treat (NNT) 
P-Value 
 
Szakacs, et al.12 0.24 0.07 - 0.71 - 0.17 - 6 0.005 
 
DISCUSSION  
 Pitolisant (formerly tiprolisant and BF2.649) is a selective histamine H3-receptor inverse 
agonist that inhibits H3-autoreceptors, activating histaminergic neurons in the brain to release 
histamine and thereby promote wakefulness.9,13 It is not yet FDA approved and therefore not 
currently available in the US. Pitolisant (brand name Wakix, in EU) was approved by the EMA 
(European Medicines Agency) in 2016 and available for use in some countries in Europe only 
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for the treatment of adults with narcolepsy with or without cataplexy.9,15 At this moment, 
pitolisant is not used for anything else other than to treat EDS and cataplexy in adults with 
narcolepsy. Pitolisant is well tolerated, with minor adverse effects such as: headaches (most 
common), nausea, insomnia, anxiety, and irritability.11-13 The contraindications of pitolisant 
include: pregnancy, severe allergic reaction to pitolisant, and severe hepatic impairment (Child-
Pugh class C).16 No known black box warnings exist at this time. Pitolisant was shown to be 
effective in reducing EDS and cataplexy with once daily dosing in the morning.  
Since pitolisant is a new drug of its class, and the first H3-receptor inverse agonist to be 
utilized in clinical trials with patients, the availability of completed primary research is scarce, 
rendering limited search results for this review. Regarding limitations of the studies themselves, 
all three articles consisted of a short duration of treatment, which may hinder pitolisant from 
reaching its maximum effectiveness and not allow assessment of tolerance of the drug. Another 
potential limitation in all three trials is that they took place in Europe, where their standards and 
regulations may be different from those followed in the US. Also, exclusion of children or those 
younger than 18 years old, patients with severe comorbidities, and those refusing placebo limit 
the ability to generalize findings to these populations. 
The phase II study by Lin et al13 was the first clinical trial done on this drug class. 
Limitations of this study included: a short-term duration of two weeks, a small sample size of 22 
patients, single-blinding, and fixed dosing. The small sample size may not be indicative of the 
population at large. Giving each patient the same dose (40mg tiprolisant) may not have allowed 
for individual efficacy of the drug. Also, with the trial being single-blinded and sequentially 
placebo-controlled, this could have invited bias into the analysis of results and patient response 
to treatment.  
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CONCLUSION 
 After reviewing the data of all three articles and despite the limitations previously 
mentioned, it is conclusive that pitolisant is an effective treatment to significantly reduce both 
EDS and cataplexy in adults with narcolepsy.11-13 Each study in this review was limited to 
narcoleptic patients in Europe, warranting future study to evaluate the effects of pitolisant on 
EDS and cataplexy on adults with narcolepsy in the US. Ongoing studies include assessing long-
term evaluation of safety and efficacy of pitolisant in narcoleptic patients.17 Also, the studies 
included in this review do not use DSM-5 criteria to define their inclusion/exclusion criteria, thus 
they did not consider the orexin levels in CSF, which is now an important diagnostic feature of 
those with narcolepsy with cataplexy. Thus, these results must be analyzed carefully because of 
possible bias in their selection of patients. Therefore, future research should diagnose according 
to DSM-5 and include its criteria in their inclusion/exclusion process. Furthermore, patients with 
narcolepsy often times complain of decreased attention and memory. H3-receptors and histamine 
are known to play a key role in learning and memory.18,19 Further research should determine the 
efficacy of pitolisant on improvement of attention and memory in patients with narcolepsy.   
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